Project Number 5U19AG010483-26 Agency/Funding Organization NIA Funding Year 2017 View Full Project Details for ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC Alzheimer's DISEASE Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category C. Translational Research and Clinical Interventions 8. Late-stage Clinical Drug Development (Phase II/III and III Clinical Trials) a. Amyloid beta Researcher and Organization Principal Investigator SPERLING, REISA A. Principal Investigator First Name REISA A. Principal Investigator Last Name SPERLING Awardee Organization UNIVERSITY OF CALIFORNIA SAN DIEGO Awardee State Massachusetts Contact PI Country United States Project Detail Funding Opportunity Announcement RFA-AG-13-001: Limited Competition: Alzheimer's Disease Cooperative Study (U19) FY Overall Cost $2,688,971 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official MCLINDEN, KRISTINA Special Initiative Accelerating Medicines Partnership - Alzheimer's Disease (AMP-AD): Biomarkers Project Alzheimer's Disease Cooperative Study (ADCS) Related Resources Repository [AlzPED] CRF receptor-1 antagonism mitigates Aβ pathology and cognitive and synaptic deficits in a mouse model of Alzheimer's disease [AlzPED] Corticotropin-Releasing Factor Receptor-1 Antagonism Reduces Oxidative Damage in an Alzheimer’s Disease Transgenic Mouse Model. [AMP-AD Knowledge Portal] Alzheimer’s Disease Cooperative Study (ADCS) Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease Trial (A4 Trial) Clinical Trial Prazosin for Agitation in Alzheimer's Disease Exercise in Adults With Mild Memory Problems Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
